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Abstract
Introduction. Biological tests of drug use can be used to inform clinical and legal decisions and hold potential to provide evidence for
epidemiological studies where self-reported behaviour may be unavailable or unreliable. We test whether hair can be considered as a
reliable marker of cannabis exposure. Methods. Hair samples were collected from 136 subjects who were self-reported heavy, light
or non-users of cannabis and tested using GC-MS/MS. Sensitivity, speciﬁcity, positive predictive value and negative predictive value
were calculated for ﬁve cannabinoids (tetrahydrocannabinol [THC], THC-OH, THC-COOH, cannabinol and cannabidiol).
Samples also were segmented in 1 cm sections representing 1month exposure and the correlation between amount of cannabinoid
detected and self-reported cannabis consumption tested.Results. All ﬁve cannabinoids were detected. Seventy-seven percent of heavy
users, 39% of light users and 0% of non-users tested positive for THC. The sensitivity of detection of THC was 0.77 (0.56–0.91)
comparing heavy cannabis smokers with light and non-users, whereas the sensitivity of other cannabinoids generally was considerably
lower. The positive and negative predictive value of detection of THC were 0.57 (0.39–0.74) and 0.91 (0.82–0.97), respectively. A
correlation of 0.52 (P<0.001) was observed between self-reported monthly cannabis use and THC.Discussion.Hair analysis can
be used as a qualitative indicator of heavy (daily or near daily) cannabis consumption within the past 3months. However, this ap-
proach is unable to reliably detect light cannabis consumption or determine the quantity of cannabis used by the individual. [Taylor
M, Lees R, Henderson G, Lingford-Hughes A, Macleod J, Sullivan J, Hickman M. Comparison of cannabinoids in hair
with self-reported cannabis consumption in heavy, light and non-cannabis users. Drug Alcohol Rev 2016;00:000-000]
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Introduction
Self-reports of cannabis use may be biassed which may
lead to problems interpreting evidence on the causes
and consequences of drug use [1,2]. Urine tests provide
a qualitative measure of recent cannabis use, and are able
to detect moderate and chronic heavy use for up to 4 and
24days later, respectively [3–5]. In contrast the detection
window for low level or infrequent cannabis use in urine is
comparatively short [6]. Cannabinoids are incorporated
into the hair shaft from the surrounding blood capillaries,
as well as from sebum and sweat that surround the hair
shaft [7,8]. Therefore, tests based on hair samples may
provide a longer detectionwindow of up to several months
and may also measure quantity of cannabis use. As hair
grows at a rate of approximately 1cm per month [9], there
is potential for the segmentation of hair samples to provide
a measure of when drug use occurred. Finally, hair analy-
sis is quick, sample collection is simple, and it is difﬁcult
for the sample to be substituted or forged.
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R E V I E W
Positive detection of cannabinoids in hair has been docu-
mented in several studies [10–13]. Skopp et al. [14] provide
the only study in which recorded dose is correlated with
biomarker. In their study, the amounts of the cannabinoids
tetrahydrocannabinol (THC), cannabidiol (CBD) and
cannabinol (CBN) were observed to increase in hair in line
with increasing cannabis consumption. However, strong
correlation between cannabinoids in hair and self-reported
use was not observed, and the study sample (n=12) was
small. Stronger evidence, therefore, is required on the
sensitivity and speciﬁcity of hair analyses for measuring
different intensities of cannabis use and how hair analysis
could be used in epidemiological and clinical studies.
In this study we examine these issues by comparing
sensitivity and speciﬁcity for ﬁve cannabis metabolites
against self-reported consumption. We also test whether
hair could provide a quantitative assessment of the
amount of cannabis consumed and if segmenting hair
into 1cm sections (representative of approximately one
month of growth) can reliably estimate monthly use.
Methods
This study was reviewed and approved by South West
(Frenchay) Research Ethics Committee (07/H0107/69). A
total of 136 participants were recruited from three sources:
the University of Bristol, the Bristol Drugs Project and the
National Health Service Bristol-based specialist drug and
alcohol service. Heavy cannabis users were recruited from
the Bristol Drugs Project [15], a project aimed at providing
support and advice to individuals with drug problems. Par-
ticipants with a range of cannabis use (none to medium)
were recruited from the University of Bristol and National
Health Service Bristol drug and alcohol service (these par-
ticipants attended this service for treatment/counselling re-
lating to a drug other than cannabis). Further information
on recruitment methods is provided elsewhere [16]. Writ-
ten and informed consent was obtained from all partici-
pants. All results were anonymised, and neither
participants nor referring services were informed of the re-
sults. Hair samples were collected from the posterior vortex
of the head, as close as possible to the scalp using scissors.
Only the proximal 3cm hair segment was used, sectioned
into either three 1cm segments or one 3cm segment, corre-
sponding to approximately the last 3months of growth.
Samples below 10mgwere subsequently excluded from
analysis (as recommended by Alere Toxicology) as below
this weight the sensitivity of the test may be compromised.
Self-reported cannabis consumption
Participants were asked to report their frequency of
cannabis use. Participants who had never tried cannabis
or last used cannabis more than 3months ago were
classed as non-users (i.e. never users/tried in the past
but do not use anymore). Based on frequency of canna-
bis consumption in the last 3months remaining partici-
pants were categorised as light cannabis users (i.e.
weekly user or less) or heavy cannabis users (i.e. daily
or near daily user).
Additional questions on number of joints/spliffs, pipes
or bongs consumed on a typical daywere used to generate
a continuousmeasure ofmonthly cannabis consumption.
Instrumentation and analysis
Analysis was performed using CTC CombiPal injector
attached to a Varian 1200 GC-MS/MS instrument. The
column used was a BPX5 SGE
(15cm×0.250×0.25μm, SGE Analytical Sciences).
Initial column temperature was set at 150°C for 1min,
and increased to 320 °C. Electron impact mode was used
for quantitative analysis. One microlitre elution solvent
was injected onto the GC-MS/MS instrument monitor-
ing four transitions:
1. 374.2>308.2
THC-D3, THC-OH-D3 and THC-COOH-D3
2. 371.2>305.2
THC, 11-hydroxy-Δ9-THC (THC-OH) and
11-nor-9-Carboxy-THC (THC-COOH)
3. 390.2>301.2
CBD
4. 367.2>310.2
CBN
Cannabinoids in hair: sample preparation
Samples were analysed at Alere Toxicology, Cardiff.
Two 1mL methanol washes were performed on the hair
with each wash being removed to waste. An additional
aliquot of methanol was added and the tubes placed in
an unheated ultrasonic bath overnight. Following
ultrasonication, the hair sample extract was then placed
in a clean test tube. Sodium hydroxide (1M) was added
to the residual hair sample. The sample was placed in a
water bath at 80°C for 30min. Following cooling the
drugs were extracted with chloroform/isopropanol
(9:1 v/v) with solid ammonium sulphate (approximately
1g) added to each sample. After centrifugation, the aque-
ous layer was aspirated to waste and the solvent layer
decanted into the tube containing the original methanol
extract. Following addition of 100μL 0.2M hydrochloric
acid in methanol, the extract was dried under vacuum.
The dried extract was reconstituted in ELISA buffer
and submitted to solid phase extraction prior to instru-
mental analysis.
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Solid phase extraction
Solid phase extraction (Waters OasisMCX μElution plates
30μm) was used to prepare samples for analysis. Using a
vacuum or positive pressure extraction box, the appropriate
quantity of solid phase extraction tubes were loaded and
conditioned with methanol followed by 0.1M acetic acid.
Each column was loaded with: 0.1M acetic acid, sample
extract is ELISA buffer (0.1M phosphate buffer pH7.2),
internal standard working solution and the remainder of
the column with 0.1 acetic acid; 0.5mL of sample (hair
extract, calibration of quality control sample) was added
to each solid phase extraction tube and eluted at a ﬂow
not exceeding 1mL/min. The loaded extract was cleaned
using 200μL 0.1M acetic acid followed by 200μL 0.1M
acetic acid:methanol (50:50). The column was dried under
vacuum or nitrogen ﬂow for 10min. Cannabinoids were
eluted with hexane and ethyl acetate (80:20v/v) under
gravity and collected into autosampler vials.
Quantiﬁcation and validation
The limit of quantiﬁcation was the lowest calibration
standard 0.05ng/mL, CBD, CBN and THC and
0.004ng/mL THC-OH and THC-COOH. Based on a
hair weight of 10mg, cut offs for samples were applied
and were 0.05ng/mg for CBD, CBN and THC, 0.4pg/
mg for THC-OH and THC-COOH. The laboratory
was blinded to the self-reported results. This method
has been validated according to the United Kingdom
Accreditation Service guidelines for ISO 17025 meeting
precision, linearity, quality control, selectivity and speci-
ﬁcity criteria. Extraction efﬁciency for THC has been
estimated from external schemes as 36% (where 100%
would correspond to complete extraction of drug from
the hair), the extraction efﬁciency of THC COOH has
been estimated at approximately 89%.
Statistics
We undertook two analyses in order to compare and esti-
mate sensitivity and speciﬁcity for ﬁve cannabinoids
(THC, THC-OH, THC-COOH, CBD and CBN) and
to test whether segmenting hair into 1cm sections gave
reliable results.
First, the sensitivity, speciﬁcity, positive predictive
value (PPV) and negative predictive value (NPV) were
calculated comparing a binary measure of cannabinoid
in hair (positive/negative) with four self-report compari-
sons: Non-users compared with light and heavy smokers;
non-users and light smokers compared with heavy
smokers; non-users compared with light smokers and
non-users compared with heavy smokers. Correlation
between the above self-reported measures and a binary
measure of THC in hair was also examined.
Second, hair samples that had been cut into 1cm seg-
ments (representing approximately 1month’s growth)
were analysed by calculating the correlation coefﬁcient,
r, between the concentration of cannabinoids in the hair
and the continuous measure of self-reported monthly
cannabis consumption. In all above analyses and
throughout this report, self-reported cannabis use was
the comparator to the hair analysis.
Results
Of the 136 participants originally recruited, 105 had hair
samples above 10mg and were included in the analysis.
There was evidence for a difference in detection of
THC in samples above and below 10mg. In samples of
self-reported heavy cannabis users, THC was detected
in 20 (77%) individuals who provided a hair sample
above 10mg. THCwas detected in 6 (32%) self-reported
heavy cannabis users who provided a hair sample below
10mg (χ2=8.19, d.f.=1, P=0.004); thus, low weight
samples were dropped from all subsequent analyses.
Over one third of the sample (39%, n=41) were non-
users of cannabis, 36% (n=38) were light users and
25% (n=26) were heavy users. Of those who reported
heavy cannabis use, 77% (n=20/26) tested positive for
THC. In contrast only 15 (39%) of 38 light users tested
positive for THC and none of 41 non-users tested posi-
tive (Table 1). In the sample as a whole, participants
smoked an average of 32.3 spliffs/joints per month (s.d.
57.44) (heavy smokers x =116, s.d.=64.10; light
smokers x =23.68, s.d.=20.29). Measured concentra-
tions of cannabinoids in hair for light and heavy cannabis
users are shown in Figure 1.
Cannabinoid detection in hair
The sensitivity and speciﬁcity were calculated for each of
the ﬁve cannabinoids. When comparing heavy cannabis
smokers with light smokers and non-users, the sensitivity
of detection of THC and CBN in hair was 0.77
(0.56–0.91) and 0.73 (0.52–0.88), respectively, whereas
the sensitivity of other cannabinoids alone was consider-
ably lower: THC-OH=0.19 (0.07–0.39), THC-
COOH=0.54 (0.33–0.73) and CBD=0.19 (0.07–0.39)
(Table 2).
The PPV and NPV were also calculated for each of the
ﬁve cannabinoids. When comparing heavy cannabis
smokers with light smokers and non-users, testing for
THC in this sample produces a PPV and NPV of 0.57
(0.39–0.74) and 0.91 (0.82–0.97) respectively. Con-
versely, when comparing heavy and light cannabis
smokers with non-users, the PPV and NPV were 1.00
(0.90–1.00) and 0.59 (0.46–0.70) respectively (Table 2).
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Hair segment analysis for cannabinoids
Sixty-nine of the samples were sectioned into three 1cm
segments. One individual had insufﬁcient hair length
for testing in segments relating to month 2 and 3,
resulting in 68 remaining individuals. 12% (n=8) of indi-
viduals had THC detected in all three sections, with 1%
(n=1) having THC-OH, 3% (n=2) having THC-
COOH, 6% (n=3) having CBD and 10% (n=7) having
CBN in all three sections of hair.
For the majority of cannabinoids, the 3cm section
(corresponding to exposure 2–3months ago) gave the
highest percentage of cannabinoid detections. The only
exception to this was CBD, where both the 1cm and
3cm sections had the highest percentage of cannabinoid
detected. The highest correlation of 0.52 (P<0.001)
was observed between self-reported heavy cannabis use
and the amount of THC in hair, with all segments show-
ing strong or moderate correlation with the self-reported
information (Table 3).
Discussion
The sensitivity of THC detection in hair was 77% in
heavy cannabis smokers compared to light and non-
cannabis users, but fell to 55% in any cannabis users
compared to non-cannabis users. Other metabolites had
lower sensitivity and speciﬁcity. The concentration of
cannabinoids detected in hair was poorly correlated with
reported levels of cannabis consumption. When using
THCas amarker to detect cannabis use comparing heavy
and light smokers with non-smokers, the PPV indicates
that >90% are true positive values. Conversely, a nega-
tive result is more difﬁcult to interpret, with the NPV
indicating that <60% with negative results are correctly
identiﬁed as such.
When segmenting hair into 1cm sections to assess the
detection of cannabinoids in ‘monthly’ segments, the
highest percentage of individuals had cannabinoids
Table 1. Descriptive data of cannabinoids detected using hair testing by self-reported cannabis smoking status
Self-report
Cannabinoid a Non-user b Light user c Heavy user d χ2 P value
THC Positive 0 (0%) 15 (39%) 20 (77%) 43.38 <0.001
Negative 41 (100%) 23 (61%) 6 (23%)
Total 41 38 26
THC-OH Positive 0 (0%) 1 (3%) 5 (19%) 11.97 0.003
Negative 41 (100%) 37 (97%) 21 (81%)
Total 41 38 26
THC-COOH Positive 0 (0%) 4 (11%) 14 (54%) 34.31 <0.001
Negative 41 (100%) 34 (89%) 12 (46%)
Total 41 38 26
Cannabidiol Positive 0 (0%) (11%) 5 (19%) 7.80 0.020
Negative 41 (100%) 34 (89%) 21 (81%)
Total 41 38 26
Cannabinol Positive 0 (0%) 11 (29%) 19 (73%) 41.64 <0.001
Negative 41 (100%) 27 (71%) 7 (26.9%)
Total 41 38 26
aCut off values to determine positive hair test result: THC, CBD and CBN=0.05ng/mg; THC-OH and THC-COOH=0.4pg/mg.
bNon-users are those who have never used cannabis or have not used cannabis in the last 3months.
cLight smokers are those who use cannabis 6 or less times per week.
dHeavy smokers are those who use cannabis more than 6 times a week.
THC, tetrahydrocannabinol.
Figure 1. Box and Whisker plot showing amount of cannabinoids detected
in the hair of non-users, light cannabis users and heavy cannabis users, where
each cannabinoid is measured in ng/mg. Non-users were not included in this
plot as none of these individuals had any of the cannabinoids detected in their
hair.
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detected in the sections corresponding to exposure three
months previous (with CBD being the only exception).
Here, we would expect more uncertainty in relation to
low level use, and results suggest that segmenting hair
into sections to obtain a measure of use over time is likely
to be unreliable.
Limitations
There are several limitations to this research that need to
be considered. First, various types of cannabis are avail-
able to users and contain different amounts of cannabi-
noids. For example, ‘skunk’ cannabis is known to have
a THC dried weight content in excess of 20% which is
far higher than non-skunk varieties which are more likely
to have a typical THC content between 2% and 8% [17].
This makes it challenging to quantify cannabis consump-
tion through hair testing. Furthermore, a cannabis ciga-
rette may contain more or less cannabis, dependent on
how the user has rolled and prepared their cigarette.
The relative ratios of tobacco compounds used may also
signiﬁcantly alter the incorporation of cannabinoids into
hair. Second, not only does THC and its main metabo-
lite, THC-COOH, have a very low incorporation rate in
comparison to other drugs, but their neutral and lipo-
philic naturemean that they do not easily bind tomelanin
[18]. Third, the lack of an additional biomarker of canna-
bis use (such as urine testing) makes the interpretation of
a speciﬁc result difﬁcult for scenarios in which the critical
determinant is absolute abstinence from cannabis. If a
hair sample tests negative for cannabinoids, it is likely that
the subject is not a heavy cannabis user, but it cannot be
determined accurately whether the individual has been
truly abstinent from cannabis. The availability of data
from urine tests would provide a replication and compar-
ison of results, therefore enabling us to determine
whether the testing of hair is sensitive enough to detect
light but not heavy use.
Comparison with other literature and implications
This study extends the previously published literature in
several ways. First, it demonstrates the use of cannabis hair
markers in a larger study than previously reported. Addi-
tionally, it covers a range of cannabis consumption, across
the categories of no, moderate and heavy cannabis use.
Skopp and colleagues [14] reported that combining results
of cannabinoids provided better correlation with self-
reported consumption data than themajority of individual
compounds. However, because of the testing procedure
here (whereby only hair screened for cannabis was sent
for conﬁrmation of THC-OH, THC-COOH, CBN and
CBD), any amalgamation of the other cannabinoid results
would result in the same sensitivity and speciﬁcity of the
THCmetabolite being observed. In comparison with pre-
vious research, the sensitivity and speciﬁcity of the canna-
bis hair test are better than the hair test for alcohol [16].
It has previously been reported that THC can be pres-
ent in the hair of non-users. THC-COOH has been pro-
posed as a better indicator of personal use as this
metabolite is only formed after cannabis consumption
meaning that a positive hair test cannot be the result of
Table 3. Correlation between self-reported monthly cannabis use and amount of cannabinoid in hair in monthly segments
Cannabinoida Monthb
Correlation
coefﬁcient (r) P value
Range
(ng/mg)c
Positive
(N)c
Negative
(N)c
Positive
(%)
Total sample
(N)
THC 1 0.52 <0.001 0.185 8 61 12 69
2 0.48 <0.001 0.170 11 57 16 68
3 0.49 <0.001 0.347 18 50 26 68
THC-OH 1 0.38 <0.001 0.001 1 68 1 69
2 0.38 0.001 0.002 3 65 4 68
3 0.42 <0.001 0.004 4 64 6 68
THC-
COOH
1 0.38 <0.001 0.004 2 67 3 69
2 0.36 0.001 0.009 4 64 6 68
3 0.39 <0.001 0.006 6 62 9 68
Cannabidiol 1 0.40 <0.001 0.050 4 65 6 69
2 0.36 0.001 0.084 3 65 4 68
3 0.36 0.001 0.068 4 64 6 68
Cannabinol 1 0.45 <0.001 0.086 7 62 10 69
2 0.51 <0.001 0.162 10 58 15 68
3 0.51 <0.001 0.154 16 52 24 68
aCannabinoid measured as a continuous measure of ng/mg in hair. bSelf-reported monthly consumption calculated from participants
answer to frequency of cannabis use and number of joints/spliffs smoked in a typical session (mean 32.30, s.d. 57.44). cPositive and
negative numbers calculated by applying cut-off values reported inmethods and Table 1, where range is range of cannabinoids in those
who tested positive. THC, tetrahydrocannabinol.
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external contamination [19,20]. However, in our sample,
we did not detect any THC or THC-COOH in non-
users and THC gave greater sensitivity and speciﬁcity
compared to THC-COOH.
The lower sensitivity for detecting any cannabis use is
likely to limit the utility of hair testing in general popula-
tion samples. For example, if we assume that in a general
population sample there are 5%heavy cannabis users and
25% light cannabis users (similar to that observed in gen-
eral population studies [21]), the PPV and NPV of the
low prevalence population (comparing non-users against
light and heavy users) would be 0.41 and 0.83 respec-
tively. In this scenario a positive result is more likely to
be false positive though a negative result is more likely
to be a true negative. Conversely, if the proportion of
heavy cannabis smokers in a sample was higher (such as
from a clinic or court) then the PPV also would be higher.
Our study has identiﬁed hair cannabinoids to be a use-
ful test to detect heavy cannabis use; however, this testing
method is unreliable when applied to low to moderate
frequency cannabis users. Furthermore, we were unable
to use hair testing to determine the quantity of cannabis
used by an individual in a speciﬁed time frame. As a
result, the real life application of hair testing for cannabis
use is likely to be limited and might not be applicable to
epidemiological surveys of the general population.
Acknowledgements
We are extremely grateful to all the individuals who took
part in this study and the individuals who helped in
recruiting them. The UK Medical Research Council
and the Wellcome Trust (Grant ref: 102215/2/12/2) and
the University of Bristol provide core support for the
Avon Longitudinal Study of Parents and Children who
are responsible for funding this study. This publication
is the work of the authors and M Taylor, M Hickman
andRLees will serve as guarantors for the contents of this
paper. This research was speciﬁcally funded by the Avon
Longitudinal Study of Parents andChildren core support
mentioned above.
References
[1] Macleod J, Hickman M, Smith GD. Reporting bias and self-reported drug
use. Addiction 2005;100:562–3.
[2] Anthony J, Neumark Y, Van Etten M. Do I do what I say? A perspective on
self-report methods in Drug Dependence Epidemiology. In: Stone A, ed.
The science of self-report: implication for research and practise. London:
Lawrence Earlbaum Associates, 2000:175–99.
[3] Wolff K, Farrell M,Marsden J, et al. A review of biological indicators of illicit
drug use, practical considerations and clinical usefulness. Addiction
1999;94:1279–98.
[4] Dolan K, Rouen D, Kimber J. An overview of the use of urine, hair, sweat
and saliva to detect drug use. Drug and Alcohol Rev 2004;23:213–7.
[5] Lowe RH, Abraham TT, Darwin WD, Herning R, Cadet JL, Huestis MA.
Extended urinary Δ9-tetrahydrocannabinol excretion in chronic cannabis
users precludes use as a biomarker of new drug exposure. Drug Alcohol De-
pend 2009;105:24–32.
[6] Johansson E, HalldinMM, Agurell S, Hollister LE, Gillespie HK. Terminal
elimination plasma half-life of Δ1-tetrahydrocannabinol (Δ1-THC) in heavy
users of marijuana. Eur J Clin Pharmacol 1989;37:273–7.
[7] Pragst F, Balikova MA. State of the art in hair analysis for detection of drug
and alcohol abuse. Clin Chim Acta 2006;370:17–49.
[8] Wennig R. Potential problems with the interpretation of hair analysis results.
Forensic Sci Int 2000;107:5–12.
[9] Harkey MR. Anatomy and physiology of hair. Forensic Sci Int 1993;63:9–18.
[10] Uhl M, Sachs H. Cannabinoids in hair: strategy to prove marijuana/hashish
consumption. Forensic Sci Int 2004;145:143–7.
[11] Musshoff F,Madea B.New trends in hair analysis and scientiﬁc demands on
validation and technical notes. Forensic Sci Int 2007;165:204–15.
[12] Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on
the acutememory and psychotomimetic effects of smoked cannabis: natural-
istic study. Br J Psychiatry 2010;197:285–90.
[13] Thieme D, Sachs H, Uhl M. Proof of cannabis administration by sensitive
detection of 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid in hair
using selective methylation and application of liquid chromatography-
tandem and multistage mass spectrometry. Drug Test Anal 2014;6:112–8.
[14] Skopp G, Strohbeck-Kuehner P, Mann K, et al. Deposition of cannabinoids
in hair after long-term use of cannabis. Forensic Sci Int 2007;170:46–50.
[15] Bristol Drugs Project (2014). Available at: http://www.bdp.org.uk/ (accessed
February 2016).
[16] LLees R, Kingston R, Williams TM, Henderson G, Lingford-Hughes A,
Hickman M. Comparison of ethyl glucuronide in hair with self-reported al-
cohol consumption. Alcohol Alcohol 2012;47:267–72.
[17] HuestisMA,Gustafson RA,Moolchan ET, et al. Cannabinoid concentrations
in hair from documented cannabis users. Forensic Sci Int 2007;169:129–36.
[18] Musshoff F,Madea B. Review of biologic matrices (urine, blood, hair) as indi-
cators of recent or ongoing cannabis use. Ther Drug Monit 2006;28:155–63.
[19] Musshoff F, Driever F, Lachenmeier K, et al. Results of hair analyses for
drugs of abuse and comparison with self-reports and urine tests. Forensic
Sci Int 2006;156:118–23.
[20] Boumba VA, Ziavrou KS, Vougiouklakis T. Hair as a biological indicator of
drug use, drug abuse or chronic exposure to environmental toxicants. Int J
Toxicol 2006;25:143–63.
[21] Heron J, Barker ED, Joinson C, et al. Childhood conduct disorder trajecto-
ries, prior risk factors and cannabis use at age 16: birth cohort study. Addic-
tion 2013;108:2129–38.
Cannabinoids in hair and self-reported consumption 7
© 2016 The Authors Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs
